Celldex Therapeutics, Inc. (CLDX)

NASDAQ: CLDX · IEX Real-Time Price · USD
29.16
0.24 (0.83%)
At close: May 20, 2022 4:00 PM
30.61
1.45 (4.97%)
After-hours:May 20, 2022 7:35 PM EDT
Market Cap1.36B
Revenue (ttm)4.14M
Net Income (ttm)-77.02M
Shares Out46.75M
EPS (ttm)-1.73
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume530,409
Open29.16
Previous Close28.92
Day's Range27.56 - 30.66
52-Week Range26.26 - 57.20
Beta2.70
AnalystsBuy
Price Target66.13 (+126.8%)
Earnings DateMay 5, 2022

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response...

IndustryBiotechnology
IPO DateMar 10, 2008
CEOAnthony Marucci
Employees132
Stock ExchangeNASDAQ
Ticker SymbolCLDX
Full Company Profile

Financial Performance

In 2021, CLDX's revenue was $4.65 million, a decrease of -37.30% compared to the previous year's $7.42 million. Losses were -$70.51 million, 18.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for CLDX stock is "Buy." The 12-month stock price forecast is 66.13, which is an increase of 126.78% from the latest price.

Price Target
$66.13
(126.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late...

HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with antih...

2 days ago - GlobeNewsWire

7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years

Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.

1 week ago - InvestorPlace

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update

HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

2 weeks ago - GlobeNewsWire

Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

HAMPTON, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporat...

2 months ago - GlobeNewsWire

Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call

HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to discu...

2 months ago - GlobeNewsWire

Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

HAMPTON, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB Leerin...

3 months ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Celldex (CLDX) Stock?

Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurig...

5 months ago - GlobeNewsWire

Celldex to Participate in Upcoming Investor Conferences

HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences...

6 months ago - GlobeNewsWire

Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -11.43% and -91.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

HAMPTON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

6 months ago - GlobeNewsWire

Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

FMR LLC's Top 5 Buys in September

FMR LLC, the Boston-based asset management company commonly known as Fidelity, disclosed this month that its top-five trades during September included new buys in Toast Inc. ( TOST , Financial), Graphit...

Other symbols:ABSIGRPHTOSTZI
7 months ago - GuruFocus

Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clin...

- Rapid and sustained improvement in urticaria control after single dose of CDX-0159 - - Greatly improved patient quality of life and reduced disease impact - - Data further support 95% complete respons...

7 months ago - GlobeNewsWire

Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference

HAMPTON, N.J., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual Global He...

7 months ago - GlobeNewsWire

Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Acad...

HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase 1b ...

7 months ago - GlobeNewsWire

Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study

Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.

8 months ago - Zacks Investment Research

Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study

HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CD...

8 months ago - GlobeNewsWire

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 15.00% and 207.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021 -

9 months ago - GlobeNewsWire

Will Celldex Therapeutics (CLDX) Report Negative Q2 Earnings? What You Should Know

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

How Good Were Celldex Therapeutics' Latest Clinical Results?

The short answer: They were impressive.

9 months ago - The Motley Fool

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option t...

HAMPTON, N.J., July 16, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offeri...

10 months ago - GlobeNewsWire

Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data

Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.

10 months ago - Zacks Investment Research